Physician profile
Thomas Vara
NPI 1457390130
$12,729.41
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.14 · 2020: $29.42 · 2021: $12K · 2022: $88.96 · 2023: $331 · 2024: $69.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.02 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,185.78 | 2021-2023 | Da Vinci Surgical System |
| Csl Behring | $145.72 | 2020-2024 | Kcentra |
| Tela Bio, INC. | $122.65 | 2021-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Integra Lifesciences Corporation | $60.43 | 2023 | Codman Certas, Codman Hakim, Cusa Clarity |
| Abbvie INC. | $39.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.27 | 2021-2023 | Gattex |
| Bioventus LLC | $17.47 | 2022 | |
| Lilly USA, LLC | $17.29 | 2024 | Zepbound, Jardiance |
| Smith+Nephew, INC. | $16.66 | 2024 | Renasys Touch |
| Kerecis Limited | $16.36 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Shionogi INC | $15.99 | 2022 | |
| Davol INC. | $14.89 | 2021 | |
| Allergan, INC. | $14.50 | 2020 | |
| Z-Medica, LLC | $13.14 | 2019 | |
| Merck Sharp & Dohme LLC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.